Cambridge UK: 17 July 2019 Tuspark has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.
Kevin Lin, President of Tuspark UK commented ‘Tony and I met at ON Helix last year, after in-depth discussion, we reached a consensus of promoting innovation network and clusters not only in Cambridge but globally. We’re delighted to be a partner of One Nucleus, which is playing a leading role in European life science and healthcare network, and we expect to…
Jul. 16, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced the global expansion of Illumina Accelerator to Cambridge, United Kingdom. Founded in the San Francisco Bay Area in 2014, Illumina Accelerator is a company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Illumina Accelerator is proud to open its first international location at Illumina’s Europe, Middle East and Africa (EMEA) headquarters in Cambridge, UK. The inaugural funding cycle of Illumina Accelerator Cambridge will begin in…
Research Triangle Park, NC, USA and Cambridge, UK, and Dubai, UAE , July 16, 2019 -- Inivata, a leader in liquid biopsy, has signed a distribution agreement with IPS Genomix, part of the IPS Group, to provide cancer patients and partners in the Middle East and Africa with access to its InVisionFirst®-Lung and InVisionSeq™ liquid biopsy tests.
The agreement will cover the UAE, Qatar, Kuwait, Bahrain, Lebanon, Jordan, Egypt, and the KSA. IPS Genomix will facilitate patient access to Inivata’s tests through both insurers and the private pay market. IPS Genomix is part…
The move will facilitate planned future growth for the successful natural products discovery and development provider
Cambridge, UK, 16th July 2019: Chesterford Research Park is delighted to confirm that Isomerase will take up occupancy within Suite 4 of the Newnham Building upon its completion in mid 2020.
Ideal for occupiers looking for grow-on space, the Newnham Building is currently being re-configured to create a detached two storey lab/R&D building situated within a prominent position on the Park. Within close reach of the popular Nucleus central facilities, the Newnham building…
Despite improving survival rates, cancer is the leading cause of death in children and young people. There is a growing need for technology to support children and young people with cancer, as well as to support health care professionals to provide optimal care.
NIHR Children and Young People MedTech Co-operative (NIHR CYP MedTech) collaborated with the Academic Health Science Network North East and North Cumbria, NIHR Clinical Research Network North East and North Cumbria, MedConnect North, and Lab4Living to deliver an innovation workshop at The Biosphere, Newcastle…
Cambridge, UK, 15 July 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director. Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programme.
Dr Mayr is Chief Technology Officer at GE Healthcare Life…
Planning to attend the BioWednesday Summer Social on 14 August 2019? Do you fancy winning one of our wise owls? By registering for the event you are automatically entered into the competiton to win one of the below owls!
Register here. Remember, One Nucleus members can attend all our BioWednesday events for free.
Terms and ConditionsThree owls to give away at the event by a random hat draw.Each person registered will be entered into the competition. You can win even if you're not in attendance (but you should still definitely attend!)
**Please note that the eyes are pins (with backings) so…
• Career that spans biotech and pharma including at Astex Pharmaceuticals and GSK
• Has led discovery of over 10 drugs taken into clinical development, including the two recent drugs from the Astex stable that have received marketing approval
• Will grow in-house drug development team to harness power of AI and take rare disease treatments from prediction through to the clinical stage
Cambridge, UK – 11 July 2019 – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific…
Westbury, NY – July 10, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
BSEP, a canalicular membrane transport protein, is responsible for bile acid efflux from hepatocytes in the liver and is of critical importance for normal bile flow and…
Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.
After meeting Matt Bratton, Senior Investment Manager from Invest Newcastle at a conference in London, businesses were keen to find out more about the UK’s life science sector as well as build academic and research partnerships. Working closely with the Department of International Trade Havana, Invest Newcastle hosted a 2-day programme as part of a UK trip to Edinburgh,…